Christian Unogu

Dr. Christian Unogu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Blazej MeczekalskiBlazej Meczekalski
Blazej Meczekalski
AKAnna Kostrzak
Anna Kostrzak
CUChristian Unogu
Christian Unogu
SBStefania Bochynska
Stefania Bochynska
MMMarzena Maciejewska-Jeske
Marzena Maciejewska-Jeske
ASAnna Szeliga
Anna Szeliga
KNDy (kisspeptine, neurokinin B, dynorphin) neurons, located in the hypothalamus, play a crucial role in the development of vasomotor symptoms (VSM) in menopausal women. Estrogen withdrawal during menopause leads to the hyperactivation of kisspeptin and neurokinin B (NKB) secretion, contributing to the onset of these symptoms. The identification of NKB/neurokinin B receptor (NK3R) signaling as a key mechanism in menopausal hot flashes has driven the development of NK3R antagonists. These antagonists restore the disrupted balance in KNDy neuron activity caused by estrogen deficiency, thereby reducing the frequency and severity of VMS. In 2023, the FDA approved fezolinetant, the first selective NK3R antagonist, for the treatment of moderate to severe VMS associated with menopause. Additionally, elinzanetant, a dual neurokinin-1 and neurokinin-3 receptor antagonist, has demonstrated promising results. The approval application for elinzanetant was supported by positive findings from the OASIS 1, 2, and 3 Phase III clinical studies. The dual antagonism of NK-1 and NK-3 receptors enhances its efficacy by alleviating menopause-related sleep disturbances and modulating peripheral vasodilatation. In this regard, elinzanetant represents a promising non-hormonal treatment that targets the underlying causes of VMS through NK-1 and NK-3 receptor pathways. The development of neurokinin B antagonist for VMS treatment exemplifies the impact of advanced pharmacological research on gynecological endocrinology.

30 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAnna Szeliga
Anna Szeliga
ADAnna Maria Duszewska
Anna Maria Duszewska
CUChristian Unogu
Christian Unogu
RSRoman Smolarczyk
Roman Smolarczyk
SBStefania Bochynska
Stefania Bochynska
EAEli Y Adashi
Eli Y Adashi
Background: Infertility remains a significant global health challenge, affecting approximately 15% of couples worldwide. In vitro fertilization (IVF) has transformed reproductive medicine; however, challenges such as low success rates in older patients, ovarian insufficiency, endometrial dysfunction, and male infertility continue to limit outcomes. Objective: This review aims to summarize the principles of IVF and explore the potential role of stem cells in enhancing IVF outcomes, with particular attention to applications in both women and men, as well as the accompanying ethical considerations. Summary: Stem cell research has introduced novel therapeutic opportunities, including ovarian rejuvenation, endometrial regeneration, sperm quality enhancement, and the development of synthetic embryo models. Mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs) demonstrate regenerative properties that may help to overcome current reproductive limitations. Despite encouraging findings from preclinical and early clinical studies, challenges such as tumorigenesis, genetic instability, and ethical controversies remain major barriers to translation. Conclusions: IVF continues to serve as a cornerstone of assisted reproductive technology (ART). Stem cell-based approaches represent an exciting frontier that could expand the therapeutic possibilities of IVF. Careful clinical validation, international regulatory harmonization, and robust ethical oversight will be essential to ensuring safe and equitable implementation.

25 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CUChristian Unogu
Christian Unogu
MGMonika Grymowicz
Monika Grymowicz
ASAnna Szeliga
Anna Szeliga
RSRoman Smolarczyk
Roman Smolarczyk
AKAnna Kostrzak
Anna Kostrzak
EAEli Y Adashi
Eli Y Adashi
Embryo implantation is a highly regulated, multistep process requiring precise synchronization between a developmentally competent blastocyst and a receptive endometrium. This article outlines the fundamental stages of implantation (apposition, adhesion, and invasion) and highlights the molecular, cellular, and immunological mechanisms underlying successful embryo–endometrial interaction. Uterine receptivity, occurring during the temporally restricted window of implantation, is governed by hormonal regulation and coordinated gene expression, and its disruption represents a key factor in infertility and recurrent implantation failure (RIF). The article further examines the multifactorial etiology of implantation failure, including genetic abnormalities, maternal age, lifestyle influences, immunological imbalance, uterine pathology, and chronic endometrial conditions. Current and emerging therapeutic strategies in assisted reproductive technology (ART) are critically reviewed, with emphasis on their efficacy and limitations. In addition, the paper explores innovative technologies aimed at improving implantation outcomes, including time-lapse imaging, artificial intelligence-based embryo selection, and transcriptomic tools such as endometrial receptivity analysis. Advanced experimental models, particularly microfluidic “womb-on-a-chip” systems and three-dimensional in vitro embryo–endometrial platforms, are highlighted as transformative tools for studying implantation dynamics and enabling personalized therapeutic approaches. Collectively, these advances offer promising avenues for improving reproductive outcomes, although further research and standardization are required to translate these innovations into routine clinical practice.

Verified
Journal Article
Open access
PDF file
CUChristian Unogu
Christian Unogu
MGMonika Grymowicz
Monika Grymowicz
ASAnna Szeliga
Anna Szeliga
RSRoman Smolarczyk
Roman Smolarczyk
AKAnna Kostrzak
Anna Kostrzak
EAEli Y Adashi
Eli Y Adashi
Background/Objectives: Embryo implantation is a highly regulated, multistep process requiring precise synchronization between a developmentally competent blastocyst and a receptive endometrium. Despite advances in reproductive medicine, implantation failure remains a major limiting factor in assisted reproductive technology (ART), particularly in cases of recurrent implantation failure (RIF). This review aims to summarize current knowledge on the molecular, cellular, and immunological mechanisms governing embryo–endometrial interaction and to evaluate contemporary strategies for optimizing implantation outcomes. Methods: This narrative review synthesizes the current literature on embryo implantation, including studies addressing uterine receptivity, etiological factors contributing to implantation failure, and emerging diagnostic and therapeutic approaches. The review integrates findings from molecular biology, clinical ART practices, and bioengineering-based models. Key areas include transcriptomic tools such as endometrial receptivity analysis, time-lapse imaging, artificial-intelligence-based embryo selection, and advanced in vitro models (e.g., microfluidic “womb-on-a-chip” systems and three-dimensional embryo–endometrial platforms). The literature was identified through major biomedical databases, following a structured but non-systematic approach. Results: Implantation success is dependent on a complex interplay of hormonal regulation, gene expression, immune modulation, and embryo quality. Disruption of uterine receptivity during the window of implantation is a critical contributor to infertility and RIF. Multiple factors—including genetic abnormalities, maternal age, lifestyle influences, immunological imbalance, uterine pathology, and chronic endometrial conditions—are implicated in implantation failure. Emerging technologies, such as AI-assisted embryo selection, transcriptomic profiling, and advanced in vitro implantation models, provide enhanced insight into implantation dynamics and offer potential for improved clinical outcomes. Conclusions: Advances in understanding embryo implantation and the development of innovative diagnostic and therapeutic technologies hold significant promise for improving reproductive success. However, further research, validation, and standardization are required before these approaches can be fully integrated into routine clinical practice. A more personalized and mechanism-based approach to implantation may ultimately enhance ART outcomes and reduce the burden of infertility.

5 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
RSRoman Smolarczyk
Roman Smolarczyk
CUChristian Unogu
Christian Unogu
ADAnna Maria Duszewska
Anna Maria Duszewska
ASAnna Szeliga
Anna Szeliga
MGMonika Grymowicz
Monika Grymowicz
Blazej MeczekalskiBlazej Meczekalski
Blazej Meczekalski
Hyperprolactinemia, defined as persistently elevated serum prolactin levels, is a common endocrine disorder with systemic metabolic consequences that extend beyond its classical roles in lactation and reproductive function. This review summarizes current evidence regarding the interplay between prolactin excess and metabolic regulation. Chronic hyperprolactinemia is associated with increased appetite, weight gain, and elevated BMI, likely mediated through altered dopaminergic tone, leptin resistance, and direct effects on adipose tissue. Dyslipidemia is frequently observed, characterized by elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, alongside reduced high-density lipoprotein cholesterol (HDL-C). Additionally, prolactin excess contributes to impaired glucose homeostasis, manifesting as increased fasting glucose levels, elevated HbA1c, and insulin resistance. Emerging data also suggest associations with endothelial dysfunction, cardiovascular risk, neuropsychiatric disturbances, and reduced bone mineral density. These findings support the conceptualization of hyperprolactinemia as a multisystem disorder requiring comprehensive clinical evaluation and management. Further studies are needed to elucidate the underlying mechanisms and optimize therapeutic strategies.